Author pages are created from data sourced from our academic publisher partnerships and public sources.
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase belonging to the HER family of receptor tyrosine kinases. Receptor activation upon ligand binding leads to down stream… Expand
AXL mediates resistance to cetuximab therapy.
The EGFR antibody cetuximab is used to treat numerous cancers, but intrinsic and acquired resistance to this agent is a common clinical outcome. In this study, we show that overexpression of the… Expand
Nuclear EGFR as a molecular target in cancer.
- T. Brand, M. Iida, Neha Luthar, Megan M. Starr, E. Huppert, D. L. Wheeler
- Radiotherapy and oncology : journal of the…
- 1 September 2013
The epidermal growth factor receptor (EGFR) has been one of the most targeted receptors in the field of oncology. While anti-EGFR inhibitors have demonstrated clinical success in specific cancers,… Expand
The nuclear epidermal growth factor receptor signaling network and its role in cancer.
The epidermal growth factor receptor (EGFR) is a member of the EGFR family of receptor tyrosine kinases (RTKs). EGFR activation via ligand binding results in signaling through various pathways… Expand
Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer
- T. Brand, M. Iida, +8 authors D. L. Wheeler
- Biology, Medicine
- Molecular Cancer Therapeutics
- 14 March 2014
Triple-negative breast cancer (TNBC) is a subclass of breast cancers (i.e., estrogen receptor–negative, progesterone receptor–negative, and HER2-negative) that have poor prognosis and very few… Expand
Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Purpose: Human papillomavirus (HPV) 16 plays an etiologic role in a growing subset of head and neck squamous cell carcinomas (HNSCC), where viral expression of the E6 and E7 oncoproteins is necessary… Expand
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Purpose: Head and neck squamous cell carcinoma (HNSCC) represents the eighth most common malignancy worldwide. Standard-of-care treatments for patients with HNSCC include surgery, radiation, and… Expand
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.
INTRODUCTION Nuclear EGFR (nEGFR) has been identified in various human tumor tissues, including cancers of the breast, ovary, oropharynx, and esophagus, and has predicted poor patient outcomes. We… Expand
Yes and Lyn play a role in nuclear translocation of the Epidermal Growth Factor Receptor
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in human cancers. Cetuximab is an anti-EGFR antibody that has been approved for use in oncology. Previously we… Expand
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for head… Expand